TZUR IGAL, Israel, Sept. 27, 2023 /PRNewswire/ -- BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the successful close of a $28 million  funding. The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz.

以色列TZUR-IGAL，2023年9月27日/PRNewswire/-BioProtect Ltd是一家专注于提供创新，可生物降解的间距解决方案的私营医疗技术公司，今天宣布成功关闭2800万美元的资金。该轮由MVM合作伙伴领导，目前的投资者参与：Triventures，KB Investments，Peregrine Ventures，Almeda Ventures和Vincent Tchenguiz的Consensus Business Group。

Proceeds from this financing will support US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer..

从这项融资中获得的收益将支持美国BioProtect球囊植入系统的商业化，该系统最近获得FDA批准，用于前列腺癌放射治疗期间的直肠保护。。

Continue Reading

继续阅读

BioProtect Balloon Implant System

BioProtect球囊植入系统

'We believe that our balloon has the potential to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy,' said BioProtect's CEO, Itay Barnea. 'To-date, our spacer has been successfully implanted in over 2,000 patients worldwide and has proven to be safe and effective.

BioProtect的首席执行官Itay Barnea说：“我们相信，在前列腺癌放射治疗过程中，我们的气球有可能彻底改变直肠保护免受辐射毒性的影响。”迄今为止，我们的垫片已成功植入全球2000多名患者，并被证明是安全有效的。

We appreciate the support of our new and existing investors who share our vision for the company, and are pleased to secure the resources to drive our penetration into the US market.'.

我们感谢新投资者和现有投资者的支持，他们分享了我们对公司的愿景，并很高兴获得资源推动我们进入美国市场。

'MVM aims to make best-in-class healthcare innovations more widely available to patients. We are impressed by the compelling benefits of BioProtect's next generation spacer and are thrilled to support the US commercial launch of this technology', said Kevin Cheng, a partner at MVM, who will be joining the company's board of directors together with his colleague Stephen Reeders..

'MVM旨在为患者提供更广泛的一流医疗保健创新。MVM的合作伙伴Kevin Cheng说，我们将与他的同事Stephen Reeders一起加入公司董事会。。

BioProtect will officially launch its balloon technology at the 2023 annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in San Diego, Oct. 1st – 4th.About BioProtectBioProtect is a technology platform company that provides innovative biodegradable spacing solutions.

BioProtect将于10月1日至4日在圣地亚哥举行的美国治疗放射与肿瘤学会（ASTRO）2023年会上正式推出气球技术。关于BioProtectBioProtect是一家提供创新的可生物降解间距解决方案的技术平台公司。

BioProtect's first application, commercially available in the US and Europe, is the BioProtect Balloon Implant System, a new generation spacer designed to provide optimal, consistent, and reproducible protection to the rectum during prostate cancer radiation therapy.For more information about BioProtect and their products, please visit www.BioProtect.com.About MVM PartnersMVM has invested in high-growth healthcare businesses since 1997.

BioProtect在美国和欧洲上市的第一个应用是BioProtect球囊植入系统，这是一种新一代垫片，旨在为前列腺癌放射治疗期间的直肠提供最佳，一致和可重复的保护。有关BioProtect及其产品的更多信息，请访问www.BioProtect.com.about MVM PartnersMVM自1997年以来已投资于高增长医疗保健业务。

With teams in Boston and London, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com. Photo - https://mma.prnewswire.com/media/2223064/BioProtect_Balloon_Implant_System.jpgSOURCE BioProtect.

MVM拥有位于波士顿和伦敦的团队，在医疗技术，制药，诊断，合同研究和制造，数字健康和其他医疗保健领域拥有广泛的全球投资前景。更多信息请访问www.mvm.com.Photo-https://mma.prnewswire.com/media/2223064/BioProtect_Balloon_Implant_System.jpgSOURCE生物保护。